upadacitinib
abbvie
[' psa', 'upadacitinib', ' upa ']
across 9 trials of upadacitinib in ra, psa and as, 40% 50% of patients had 2 cv risk factors, 65 years 6% 23%. rates of adjudicated mace and vte with upa were infrequent, consistent with background rates in ra, psa, and as abst 0510 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach